{
  "docId": "019de073-b144-743c-94c4-bc5a80eb44df",
  "docSlug": "9540d42c57dd536e8cb82c97bd211004",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 50 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 18,
  "pageCount": 50,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "context",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Slide 18 of the deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-b144-743c-94c4-bc5a80eb44df/18",
  "deckHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df",
  "deckJsonHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df.json",
  "deckAnchorHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.123,
        "x": 0.784,
        "y": 0.263
      },
      "kind": "callout",
      "text": "QIDP, Fast Track and Priority Review Designations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "616fc7d4-e0ac-4215-a779-fbc2d003ab3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.65,
        "x": 0.063,
        "y": 0.25
      },
      "kind": "list",
      "text": "XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. This marks the first FDA-approved product in Daré’s portfolio of potential first-in-category development candidates. XACIATO is expected to be available commercially in the U.S. in 4Q 2022. Supply to support commercial launch expected earliest summer 2022.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78880918-c887-4d8c-bde1-23a0ac567e25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.103,
        "x": 0.794,
        "y": 0.665
      },
      "kind": "paragraph",
      "text": "NDA Approved December 7, 2021",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64b81b7f-c491-4401-92ba-48e8c6e3fdd8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.242,
        "x": 0.379,
        "y": 0.025
      },
      "kind": "title",
      "text": "XACIATO: Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bad3e284-889f-4f77-8a84-80f3c67a9e54",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 18,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e9054d9b-fe14-4a0d-ab5b-ea433a23ce55",
      "evidence": "The problem statement and context on pages 17-18 suggest a cost of inaction loop.",
      "position": 1,
      "objective": "What is the cost of not addressing women's health?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}